Wikisage, the free encyclopedia of the second generation, is digital heritage
Epilepsy: Difference between revisions
Jump to navigation
Jump to search
m (wlink) |
No edit summary |
||
| (57 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Classification of ethiology could divided in four categories: | Classification of ethiology could divided in four categories: | ||
*idiopathic epilepsy | *[[idiopathic epilepsy]] | ||
*symptomatic epilepsy | *symptomatic epilepsy | ||
*provoked epilepsy | *provoked epilepsy | ||
*cryptogenic epilepsy | *[[cryptogenic epilepsy]] | ||
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2011.03041.x/epdf The etiologic classification of epilepsy]</ref> | <ref>[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2011.03041.x/epdf The etiologic classification of epilepsy]</ref> | ||
It is difficult to distinguish between genetic and cryptogenic syndromes. | It is difficult to distinguish between genetic and cryptogenic syndromes. | ||
Morbility data is difficult to interpret when WHO states 50 millions persons | Morbility data is difficult to interpret when [[World Health Organization|WHO]]<ref>http://www.who.int/en/</ref> states 50-70 millions persons<ref>(Li et al 2014)</ref> suffers '''epilepsy'''<ref>(Chung 2015)</ref> | ||
nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance with [[antiepileptic drug|AED]]<ref>(Davis et al 2008)</ref> | |||
[[File: 1Eslicarbazepine acetate structure.svg.png|thumb|left|[[eslicarbazepine]]]] | |||
{| class="toccolours float-right taxobox pilze" style="font-size:80%;" cellpadding="3" cellspacing="3" | {| class="toccolours float-right taxobox pilze" style="font-size:80%;" cellpadding="3" cellspacing="3" | ||
| colspan="3" background-color:#000000;" | | | colspan="3" background-color:#000000;" | | ||
| Line 23: | Line 22: | ||
|[[,,,,]] | |[[,,,,]] | ||
|- style="vertical-align:top; background:#ffffff;" | |- style="vertical-align:top; background:#ffffff;" | ||
|align="left" style="background:#99ff99"|'''INN''' |||[[Generic]] | |align="left" style="background:#99ff99"|'''[[International Nonproprietary Name|INN]]''' |||[[Generic]] | ||
|slow release | |slow release | ||
|- style="vertical-align:top; background:#ffffff;" | |- style="vertical-align:top; background:#ffffff;" | ||
| Line 29: | Line 28: | ||
|xr | |xr | ||
|- style="vertical-align:top; background:#ffffff;" | |- style="vertical-align:top; background:#ffffff;" | ||
|align="left" style="background:#99ff99"|'''lamotrigine''' |||[[normal]] | |align="left" style="background:#99ff99"|'''[[lamotrigine]]''' |||[[normal]] | ||
|xr | |[[Lamictal XR]]<ref>http://www.rxlist.com/lamictal-xr-drug.htm</ref> | ||
|- style="vertical-align:top; background:#ffffff;" | |- style="vertical-align:top; background:#ffffff;" | ||
|align="left" style="background:#99ff99"|'''levetiracetam''' ||[[normal]] | |align="left" style="background:#99ff99"|'''[[levetiracetam]]''' ||[[etiracetam|normal]] | ||
|xr | |[[Levetiracetam XR|xr]] | ||
|- style="vertical-align:top; background:#ffffff;" | |- style="vertical-align:top; background:#ffffff;" | ||
|align="left" style="background:#99ff99"|'''oxcarbazepine''' ||[[ | |align="left" style="background:#99ff99"|'''oxcarbazepine''' ||[[oxcarbazepine]] | ||
|xr | |xr | ||
|- style="vertical-align:top; background:#ffffff;" | |- style="vertical-align:top; background:#ffffff;" | ||
|align="left" style="background:#99ff99"|''' | |align="left" style="background:#99ff99"|'''[[phenytoin]]''' ||[[...]] | ||
|xr | |xr | ||
|-style="vertical-align:top; background:#ffffff;" | |-style="vertical-align:top; background:#ffffff;" | ||
|align="left" style="background:#99ff99"|'''valproate''' || | |align="left" style="background:#99ff99"|'''[[valproate]]''' || | ||
|colspan="3" | xr | |colspan="3" | [[Valproate_XR| xr]] | ||
|-style="vertical-align:top; background:#ffffff;" | |-style="vertical-align:top; background:#ffffff;" | ||
|align="left" style="background:#99ff99"|''' | |align="left" style="background:#99ff99"|'''[[topiramate]]''' || | ||
|colspan="3" | [[XR- | |colspan="3" | [[XR-topiramate|xr]] | ||
|- | |- | ||
| colspan="3" style="text-align:center; font-size:120%; background-color:#32CD32;" | | | colspan="3" style="text-align:center; font-size:120%; background-color:#32CD32;" | | ||
| Line 52: | Line 51: | ||
|} | |} | ||
[[File:Riluzole.svg.png|thumb|[[riluzole]]]] | |||
[[File:2000px-Sultiame.svg.png|thumb|sulthiame]] | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures] | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448990/pdf/prp20003-e00124.pdf Eslicarbazepine acetate for the treatment of focal epilepsy:an update on its proposed mechanisms of action] | |||
[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2011.03140.x/pdf In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein] | |||
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1562526/pdf/nihms11506.pdf Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline] | |||
==[[International League Against Epilepsy |ILAE]] Classification== | ==[[International League Against Epilepsy |ILAE]] Classification== | ||
<ref>http://www.who.int/mediacentre/factsheets/fs999/en/</ref> | <ref>http://www.who.int/mediacentre/factsheets/fs999/en/</ref> | ||
<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325583/pdf/i1535-7511-14-6-339.pdf epilepsy is not resolved. Epilepsy Currents 14 2014]</ref> | |||
<ref>https://www.ligaepilepsia.cl/epilepsias/tipos-de-epilepsia</ref> | <ref>https://www.ligaepilepsia.cl/epilepsias/tipos-de-epilepsia</ref> | ||
<ref>Annie T Berg et al.2010 Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009 [http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2010.02522.x/epdf Epilepsia 51 676-685]</ref> | |||
[http://www.ilae.org/visitors/centre/documents/OrganizationEpilepsy-overview.pdf ILAE Overview] | |||
===See also=== | |||
[http://www.ilae.org/Visitors/Publications/documents/ED_Arzimanoglou_2013.pdf A new perspective for Epileptic Disorders] | [http://www.ilae.org/Visitors/Publications/documents/ED_Arzimanoglou_2013.pdf A new perspective for Epileptic Disorders] | ||
==Links== | ==Links== | ||
{{Wikidata|Q41571}} | |||
[http://www.nice.org.uk/guidance/cg137/resources/epilepsies-diagnosis-and-management-35109515407813 Epilepsies: diagnosis and management clinical guide] | |||
[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2007.01414.x/pdf Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population] | [http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2007.01414.x/pdf Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population] | ||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499082/pdf/IJPH-43-1616.pdf The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis] | |||
[http://onlinelibrary.wiley.com/doi/10.1111/epi.12182/epdf The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs] | |||
[http://www.scholarpedia.org/w/index.php?title=Models_of_epilepsy&oldid=140675 Models of epilepsy] | |||
[https://www.frontiersin.org/articles/10.3389/fphar.2017.00661/full purinergic signalling:therapeutic developments] | |||
[https://www.ncbi.nlm.nih.gov/pubmed/28993753 Electroencephalography in the Diagnosis of Genetic Generalized Epilepsy Syndromes] | |||
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613169/ Ranking the Leading Risk Factors for Sudden Unexpected Death in Epilepsy] | |||
[[Lennox–Gastaut_syndrome|Lennox-Gastaut Syndrome]] | |||
[[BECTS]] | |||
[[Dravet's syndrome]] | [[Dravet's syndrome]] | ||
[[Status epilepticus]] | |||
:[[Panayiotopoulos syndrome]] | |||
:[[epilepsia partialis continua]] | |||
[[West's syndrome]] | |||
[[Ohtahara syndrome]] | |||
[[Pretzel syndrome]] | |||
[[Doose syndrome]] | |||
[[Category:Disease]] | |||
[[Category:Neurological disorder]] | |||
{{refs}} | {{refs}} | ||
[[nl:epilepsie]] | [[nl:epilepsie]] | ||
Latest revision as of 23:16, 29 January 2023
Classification of ethiology could divided in four categories:
- idiopathic epilepsy
- symptomatic epilepsy
- provoked epilepsy
- cryptogenic epilepsy
[1] It is difficult to distinguish between genetic and cryptogenic syndromes.
Morbility data is difficult to interpret when WHO[2] states 50-70 millions persons[3] suffers epilepsy[4]
nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance with AED[5]
|
Medicines | ||||
| type | ,,, | ,,,, | ||
| INN | Generic | slow release | ||
| carbamazepine | normal | xr | ||
| lamotrigine | normal | Lamictal XR[6] | ||
| levetiracetam | normal | xr | ||
| oxcarbazepine | oxcarbazepine | xr | ||
| phenytoin | ... | xr | ||
| valproate | xr | |||
| topiramate | xr | |||
|
AED | ||||
Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline
ILAE Classification
[7] [8] [9] [10] ILAE Overview
See also
A new perspective for Epileptic Disorders
Links
Epilepsies: diagnosis and management clinical guide
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population
The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis
The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs
purinergic signalling:therapeutic developments
Electroencephalography in the Diagnosis of Genetic Generalized Epilepsy Syndromes
Ranking the Leading Risk Factors for Sudden Unexpected Death in Epilepsy
| References: |
|